Formation and Business of the Company	6 Months Ended
Jun. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Formation and Business of the Company	1. Formation and Business of the Company Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, to reduce the frequency and severity of allergic reactions, including anaphylaxis, upon exposure to peanut and other food allergens. Our therapeutic approach, which we refer to as Characterized Oral Desensitization Immunotherapy, or CODIT^TM, is designed to desensitize patients to food allergens using rigorously characterized biologic products, defined treatment protocols and tailored support services. We are headquartered in Brisbane, California, and were incorporated in the state of Delaware on June 24, 2011. Since inception, we have incurred net losses and negative cash flows from operations. During the quarter and six months ended June 30, 2019, we incurred a net loss of $62.9 million and $117.1 million, respectively, and we used $92.0 million of cash in operations. As of June 30, 2019, we had an accumulated deficit of $593.3 million, and we do not expect to experience positive cash flows in the near future. As of June 30, 2019, we had cash, cash equivalents and investments of $250.3 million. We believe that our existing capital resources will be sufficient to fund our planned operations for at least the next 12 months and through expected regulatory approval and potential commercial launch in the United States and Europe for AR101, our lead CODIT^TMproduct candidate. We have financed our operations to date primarily through private placements of our equity securities, our initial public offering, or IPO, of common stock in August 2015, an underwritten public offering of common stock in February and March 2018 and our loan agreement entered into in January 2019. Our ability to continue to meet our obligations and to achieve our business objectives is dependent upon a number of factors, which include obtaining U.S. Food and Drug Administration, or FDA, and European Medicines Agency, or EMA, approval, raising additional capital, the successful and timely completion of our clinical trials, our ability to control expenses and generating sufficient revenue in the United States and Europe. Failure to obtain FDA and EMA approval, commercialize our lead product candidate, manage discretionary expenditures, or raise additional financing, as required, may adversely impact our ability to achieve our intended business objectives.

Formation and Business of the Company

6 Months Ended

Jun. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

1. Formation and Business of the Company

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, to reduce the frequency and severity of allergic reactions, including anaphylaxis, upon exposure to peanut and other food allergens. Our therapeutic approach, which we refer to as Characterized Oral Desensitization Immunotherapy, or CODIT^TM, is designed to desensitize patients to food allergens using rigorously characterized biologic products, defined treatment protocols and tailored support services. We are headquartered in Brisbane, California, and were incorporated in the state of Delaware on June 24, 2011.

Since inception, we have incurred net losses and negative cash flows from operations. During the quarter and six months ended June 30, 2019, we incurred a net loss of $62.9 million and $117.1 million, respectively, and we used $92.0 million of cash in operations. As of June 30, 2019, we had an accumulated deficit of $593.3 million, and we do not expect to experience positive cash flows in the near future. As of June 30, 2019, we had cash, cash equivalents and investments of $250.3 million. We believe that our existing capital resources will be sufficient to fund our planned operations for at least the next 12 months and through expected regulatory approval and potential commercial launch in the United States and Europe for AR101, our lead CODIT^TMproduct candidate. We have financed our operations to date primarily through private placements of our equity securities, our initial public offering, or IPO, of common stock in August 2015, an underwritten public offering of common stock in February and March 2018 and our loan agreement entered into in January 2019. Our ability to continue to meet our obligations and to achieve our business objectives is dependent upon a number of factors, which include obtaining U.S. Food and Drug Administration, or FDA, and European Medicines Agency, or EMA, approval, raising additional capital, the successful and timely completion of our clinical trials, our ability to control expenses and generating sufficient revenue in the United States and Europe. Failure to obtain FDA and EMA approval, commercialize our lead product candidate, manage discretionary expenditures, or raise additional financing, as required, may adversely impact our ability to achieve our intended business objectives.